Dr. Hirsch S. Mehta, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
3131 Berger Ave, Suite 200
San Diego, CA 92123
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 960
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2007Medical school: Hahnemann University College of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CA license A105910 (first issued 2008; current) -
Cardiovascular Disease Physician
CA license A105910 (first issued 2008; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Sharp Memorial Hospital San Diego, CA
- Grossmont Hospital La Mesa, CA
- Sharp Chula Vista Medical Center Chula Vista, CA
- Sharp Coronado Hospital and Hlthcr Ctr Coronado, CA
Medical groups
- Emergency and Acute Care Medical Corporation (422 clinicians)
- San Diego Cardiac Center Medical Group Inc. (22 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 960
- Services billed
- 5,051
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 639 | 120 |
| Established patient office or other outpatient visit, 40-54 minutes | 633 | 291 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 494 | 116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 431 | 419 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 342 | 266 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 243 | 93 |
| Established patient office or other outpatient visit, 30-39 minutes | 151 | 118 |
| Heart muscle strain imaging | 131 | 129 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 127 | 72 |
| Evaluation of lower heart chamber assist device | 119 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 190 payments worth $93,246 in total to this clinician.
| Alnylam Pharmaceuticals Inc. | $33,534 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $27,521 |
| Bridgebio Pharma, Inc. | $13,738 |
| Lilly USA, LLC | $7,103 |
| E.r. Squibb & Sons, L.l.c. | $4,869 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,101 |
| AstraZeneca Pharmaceuticals LP | $1,160 |
| Cvrx, Inc. | $170 |
| Compensation for services other than consulting (speaking, faculty) | $83,195 |
|---|---|
| Consulting Fee | $4,224 |
| Food and Beverage | $3,854 |
| Travel and Lodging | $1,974 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $11,340 |
| Actelion Pharmaceuticals US, Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $6,540 |
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| Actelion Pharmaceuticals US, Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Actelion Pharmaceuticals US, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Bridgebio Pharma, Inc. Oct 14, 2025 | Consulting Fee Attruby · Cardiomyopathy | $3,150 |
All 43 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,400 |
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $2,520 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,400 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,850 |
| Actelion Pharmaceuticals US, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Alnylam Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Alnylam Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $2,520 |
| Actelion Pharmaceuticals US, Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Bridgebio Pharma, Inc. Oct 14, 2025 | Consulting Fee Attruby · Cardiomyopathy | $3,150 |
| E.r. Squibb & Sons, L.l.c. Oct 8, 2025 | Travel and Lodging CAMZYOS · Cardiovascular · travel to San Diego, CA | $15.00 |
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| Alnylam Pharmaceuticals Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| AstraZeneca Pharmaceuticals LP Aug 20, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,074 |
| Alnylam Pharmaceuticals Inc. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Alnylam Pharmaceuticals Inc. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Actelion Pharmaceuticals US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Lilly USA, LLC Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,080 |
| Lilly USA, LLC Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $770 |
| Bridgebio Pharma, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,400 |
| Actelion Pharmaceuticals US, Inc. Jul 2, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Denver, CO | $57.00 |
| Actelion Pharmaceuticals US, Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $6,540 |
| Alnylam Pharmaceuticals Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $2,520 |
| Bridgebio Pharma, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $3,150 |
| Bridgebio Pharma, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,100 |
| Bridgebio Pharma, Inc. Jun 12, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV | $123 |
| Bridgebio Pharma, Inc. Jun 12, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV | $57.00 |
| Actelion Pharmaceuticals US, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $11,340 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA | $100 |
| Bridgebio Pharma, Inc. May 28, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV · in-kind | $282 |
| Bridgebio Pharma, Inc. May 28, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV · in-kind | $250 |
| Bridgebio Pharma, Inc. May 28, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV · in-kind | $250 |
| Lilly USA, LLC May 27, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,040 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,040 |
| Alnylam Pharmaceuticals Inc. Apr 26, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $29.14 |
| Alnylam Pharmaceuticals Inc. Apr 25, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $567 |
| Alnylam Pharmaceuticals Inc. Apr 25, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Boston, MA · in-kind | $243 |
| Lilly USA, LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,040 |
| Actelion Pharmaceuticals US, Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $545 |
| Actelion Pharmaceuticals US, Inc. Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
| Lilly USA, LLC Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,040 |
| Lilly USA, LLC Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,040 |
| Actelion Pharmaceuticals US, Inc. Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $3,270 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $48,642 in research payments for these studies, mostly to the institutions running them.
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Boston Scientific Corporation · Completed · NCT04790344 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.